Everest Medicines Receives $280 Million from Gilead’s Immunomedics Following Partnership Cancellation
China-based Everest Medicines (HKG: 1952) has announced a significant financial development, receiving a full upfront...
March 2023
Akeso Biopharma and LaNova Medicines Collaborate on Clinical Studies for Cancer Therapies
China-based Akeso Biopharma (HKG: 9926) has announced a strategic partnership with fellow Chinese firm LaNova...
Lee’s Pharmaceutical Subsidiary Secures Distribution Deal for NVK002 in South Korea
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950), through its subsidiary Zhaoke Ophthalmology Ltd (HKG: 6622),...
Sihuan Pharmaceutical’s XZP-KM602 and XZP-6877 Secure Clinical Trial Approvals for Solid Tumors
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its minority-owned subsidiary, Xuanzhu...
Shenzhen YHLO Biotech Partners with NCRCID for Advanced Tuberculosis Diagnostics
China-based Shenzhen YHLO Biotech Co., Ltd has announced a strategic partnership with the National Clinical...
Everest Medicines Receives $280 Million from Gilead Sciences for Partnership Cancellation
China-based Everest Medicines (HKG: 1952) has announced that it has received a full upfront payment...
Akeso Biopharma and LaNova Medicines Collaborate on AK112 and LM-302 Combo for Solid Tumors
China-based Akeso Biopharma (HKG: 9926) has entered into a strategic partnership with compatriot firm LaNova...
CSPC Pharmaceutical’s mRNA Vaccine SYS6006 Receives Emergency Use Authorization in China
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has revealed that it has obtained an Emergency...
CDE Launches Technical Guidelines for Pediatric Anti-tumor Drug Clinical R&D
The Center for Drug Evaluation (CDE) has released a set of Technical Guidelines focused on...
Huarun Pharmaceutical Co., Ltd Announces Private Placement to Fund Expansion Projects
China-based Huaren Pharmaceutical Co., Ltd is set to raise RMB 1.34 billion (USD 194.8 million)...
CDE Releases Guidance on Pre-Phase III Clinical Trial Meetings for Innovative Chemical Drugs
The Center for Drug Evaluation (CDE) has released the “Innovative Chemical Drug Pre-Phase III Clinical...
Everest Medicines Partners with Guangdong Provincial People’s Hospital in Kidney Disease Research
China-based Everest Medicines Ltd (HKG: 1952) has announced a comprehensive strategic partnership with Guangdong Provincial...
Sihuan Pharmaceutical’s KM501 Receives Clinical Trial Approval for HER2-Positive Tumors
China-based Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...
4B Technologies’ FB1001 Receives CDE Approval for Clinical Trials
China-based 4B Technologies Investments Ltd has announced that it has received clinical trial approval from...
RemeGen’s RC48 Receives Two Clinical Trial Approvals for Breast Cancer Treatments
RemeGen Ltd (HKG: 9995) has announced the receipt of two clinical trial approvals for its...
China’s Plan to Strengthen Medical and Healthcare Service System Unveiled
The General Office of the CPC Central Committee and State Council has released the “Opinions...
Alphax Bio Raises Millions for Spatial Proteomics and Tumor Immune Microenvironment Research
Beijing-based Alphax Bio, a developer of immune-testing technologies, has reportedly raised “tens of millions” of...
Luye Pharma’s Lurbinectedin Gains Priority Review Status for SCLC Treatment
The Center for Drug Evaluation (CDE) website indicates that China-based Luye Pharma Group’s (HKG: 2186)...
Guangdong Zhongsheng’s RAY1216 Receives Conditional Approval for COVID-19 Treatment
China-based Guangdong Zhongsheng Pharmaceutical Co., Ltd (SHE: 002317) has announced that it has received conditional...
Hengrui Pharmaceuticals’ HRS-5965 Receives NMPA Approval for Clinical Study in Hemolytic Anemia
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has announced that it has received approval...